<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076942</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00601</org_study_id>
    <nct_id>NCT05076942</nct_id>
  </id_info>
  <brief_title>Groningen International Study on Sentinel Nodes in Vulvar Cancer-III</brief_title>
  <acronym>GROINSS-VIII</acronym>
  <official_title>Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vulvar cancer patients with SN-metastasis &gt; 2mm will receive chemoradiation instead of an&#xD;
      inguinofemoral lymphadenectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Standard treatment of early stage vulvar cancer is a wide local excision of the primary tumor&#xD;
      combined with the sentinel node (SN) procedure for the groins. An inguinofemoral&#xD;
      lymphadenectomy (IFL) is only indicated in case of a positive SN. An IFL is associated with&#xD;
      major morbidity, e.g. wound healing problems, lymphoceles, lymphedema of the legs and&#xD;
      recurrent infections. GROINSS-V II investigated whether radiotherapy would be a safe&#xD;
      alternative for IFL in case of SN metastasis. The results for radiotherapy in the group with&#xD;
      metastasis ≤ 2mm are promising. This study also showed that for metastasis &gt; 2mm, only&#xD;
      radiotherapy was not efficient. The efficacy of treatment can be increased by adding&#xD;
      chemotherapy or giving a higher dose of radiotherapy. GROINSS-V III will investigate this&#xD;
      regimen.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The primary objective of this study is to investigate the safety of replacing inguinofemoral&#xD;
      lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a&#xD;
      macrometastasis (&gt;2mm) and/or extracapsular extension in the SN. The secondary objective is&#xD;
      to evaluate the short and long-term morbidity associated with the SN procedure and&#xD;
      chemoradiation.&#xD;
&#xD;
      Study design: Phase II treatment trial, with stopping rules for the incidence of groin&#xD;
      recurrences.&#xD;
&#xD;
      Study population: early-stage vulvar cancer patients with a metastasis &gt; 2mm in their SN, or&#xD;
      more than one metastasis ≤ 2mm.&#xD;
&#xD;
      Intervention: Participants will be treated with chemoradiation, in a total dose of 56Gy to&#xD;
      the involved site, combined with weekly cisplatin 40mg/m2&#xD;
&#xD;
      Main study parameters/endpoints: The primary endpoint is the groin recurrence rate in the&#xD;
      first 2 years after primary treatment.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: participants will be treated with chemoradiation during 5 weeks instead of&#xD;
      surgical treatment. There is a risk that this treatment will not be as effective as surgical&#xD;
      treatment, which may lead to more groin recurrences which are hard to treat. By continuously&#xD;
      monitoring the groin recurrence rate the investigators will notice activation of the stopping&#xD;
      rule as early as possible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>phase II treatment trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Groin recurrence rate</measure>
    <time_frame>Within first 2 years after primary treatment</time_frame>
    <description>Groin recurrence in the groin with SN metastasis treated with chemoradiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related morbidity</measure>
    <time_frame>First two years after primary treatment</time_frame>
    <description>Short and longterm morbidty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed using EORTC-QLQc30</measure>
    <time_frame>First two year after primary treatment</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life-vulvar cancer specific, as assessed using VU34</measure>
    <time_frame>First two year after primary treatment</time_frame>
    <description>Quality of life-vulvar cancer specific</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">157</enrollment>
  <condition>Vulvar Cancer</condition>
  <condition>Sentinel Lymph Node</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>Chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inguinofemoral radiotherapy (48-50 Gy in 1.8 Gy daily fractions, with a boost dose to the involved inguinal site for a total equivalent dose of 56 Gy over 5-6 weeks, preferably with simultaneous integrated boost technique) combined with weekly cisplatin 40 mg/m2 intravenously on days 1, 8, 15, 22 and 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy combined with cisplatin</intervention_name>
    <description>Inguinofemoral radiotherapy combined with weekly cisplatin</description>
    <arm_group_label>Chemoradiation</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Inguinofemoral radiotherapy combined with weekly cisplatin</description>
    <arm_group_label>Chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmed primary SCC of the vulva&#xD;
&#xD;
          -  T1 tumor, not encroaching urethra/vagina/anus&#xD;
&#xD;
          -  Depth of invasion &gt; 1mm&#xD;
&#xD;
          -  Tumor diameter &lt; 4cm&#xD;
&#xD;
          -  Unifocal tumor&#xD;
&#xD;
          -  No enlarged (&gt;1.5cm) or suspicious inguinofemoral lymph nodes at imaging&#xD;
             (CT/MRI/ultrasound)&#xD;
&#xD;
          -  Possibility to obtain informed consent&#xD;
&#xD;
          -  Metastatic sentinel lymph node; size of metastasis &gt; 2mm and / or extracapsular&#xD;
             extension, or&#xD;
&#xD;
          -  Metastatic sentinel lymph node: more than 1 SN with metastasis ≤ 2mm&#xD;
&#xD;
          -  Patients are able to understand requirements of study, provide written informed&#xD;
             consent and comply with the study and follow-up procedures&#xD;
&#xD;
          -  Adequate bone marrow, renal and liver function:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 109 /L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109 /L&#xD;
&#xD;
               -  Creatinine clearance ≥ 40 ml/min measured by the Cockroft Gault formula&#xD;
&#xD;
               -  Total bilirubin &lt; 1.25 x ULN Aspartate transaminase (AST) and alanine&#xD;
                  transaminase (ALT) ≤ 2.5 x ULN&#xD;
&#xD;
          -  Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale&#xD;
             (Appendix A)&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Life expectancy of ≥ 12 weeks&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inoperable tumors and tumors &gt; 4cm&#xD;
&#xD;
          -  Multifocal tumors&#xD;
&#xD;
          -  Tumors with other pathology than squamous cell carcinoma&#xD;
&#xD;
          -  Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine&#xD;
             needle aspiration cytology&#xD;
&#xD;
          -  No other carcinomas, other than basal cell carcinomas, within last 5 years&#xD;
&#xD;
          -  History of pelvic radiotherapy&#xD;
&#xD;
          -  History of any infection requiring hospitalization or antibiotics within 2 weeks&#xD;
             before enrollment&#xD;
&#xD;
          -  Pregnant female or nursing mother&#xD;
&#xD;
          -  Desire to become pregnant&#xD;
&#xD;
          -  Known brain or spinal cord metastases unless adequately treated (surgery or&#xD;
             radiotherapy) with no evidence of progression and neurologically stable off&#xD;
             anticonvulsants and steroids&#xD;
&#xD;
          -  Unstable angina, myocardial infarction, cerebrovascular accident, &gt; Class II&#xD;
             congestive heart failure according to the New York Heart Association Classification&#xD;
             for Congestive Heart Failure (see Appendix B) within 6 months before enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maaike H Oonk, MD PhD</last_name>
    <phone>+31-50-3613000</phone>
    <email>m.h.m.oonk@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liza Lahaye</last_name>
    <email>eventinbox@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9712RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maaike H Oonk, MD PhD</last_name>
      <phone>+31-50-3613000</phone>
      <email>m.h.m.oonk@umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Maaike Oonk</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

